Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.78
FLML's Cash to Debt is ranked lower than
81% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. FLML: 0.78 )
Ranked among companies with meaningful Cash to Debt only.
FLML' s Cash to Debt Range Over the Past 10 Years
Min: 0.08  Med: 11.96 Max: N/A
Current: 0.78
Equity to Asset 0.07
FLML's Equity to Asset is ranked lower than
91% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. FLML: 0.07 )
Ranked among companies with meaningful Equity to Asset only.
FLML' s Equity to Asset Range Over the Past 10 Years
Min: -0.32  Med: 0.53 Max: 0.8
Current: 0.07
-0.32
0.8
F-Score: 4
Z-Score: -0.54
M-Score: 23.15
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -50.83
FLML's Operating margin (%) is ranked higher than
53% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. FLML: -50.83 )
Ranked among companies with meaningful Operating margin (%) only.
FLML' s Operating margin (%) Range Over the Past 10 Years
Min: -1285  Med: -121.51 Max: -26.53
Current: -50.83
-1285
-26.53
Net-margin (%) -53.66
FLML's Net-margin (%) is ranked higher than
53% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. FLML: -53.66 )
Ranked among companies with meaningful Net-margin (%) only.
FLML' s Net-margin (%) Range Over the Past 10 Years
Min: -1027.16  Med: -72.90 Max: -24.2
Current: -53.66
-1027.16
-24.2
ROE (%) -135.32
FLML's ROE (%) is ranked lower than
87% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. FLML: -135.32 )
Ranked among companies with meaningful ROE (%) only.
FLML' s ROE (%) Range Over the Past 10 Years
Min: -1103.89  Med: -26.74 Max: -10.71
Current: -135.32
-1103.89
-10.71
ROA (%) -24.23
FLML's ROA (%) is ranked higher than
52% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. FLML: -24.23 )
Ranked among companies with meaningful ROA (%) only.
FLML' s ROA (%) Range Over the Past 10 Years
Min: -58.46  Med: -16.40 Max: -3.46
Current: -24.23
-58.46
-3.46
ROC (Joel Greenblatt) (%) -197.41
FLML's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. FLML: -197.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
FLML' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1730.55  Med: -86.72 Max: -35.4
Current: -197.41
-1730.55
-35.4
Revenue Growth (3Y)(%) -32.30
FLML's Revenue Growth (3Y)(%) is ranked lower than
77% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. FLML: -32.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
FLML' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -52.8  Med: -1.20 Max: 42.6
Current: -32.3
-52.8
42.6
EBITDA Growth (3Y)(%) 106.50
FLML's EBITDA Growth (3Y)(%) is ranked higher than
98% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. FLML: 106.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
FLML' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -50.2  Med: -15.00 Max: 126.3
Current: 106.5
-50.2
126.3
EPS Growth (3Y)(%) 90.20
FLML's EPS Growth (3Y)(%) is ranked higher than
97% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. FLML: 90.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
FLML' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -38.4  Med: -17.20 Max: 90.2
Current: 90.2
-38.4
90.2
» FLML's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

FLML Guru Trades in

FLML Guru Trades in

Q1 2015

FLML Guru Trades in Q1 2015

Steven Cohen 355,800 sh (New)
» More
Q2 2015

FLML Guru Trades in Q2 2015

Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with FLML

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 8.96
FLML's Forward P/E is ranked higher than
78% of the 343 Companies
in the Global Biotechnology industry.

( Industry Median: 16.58 vs. FLML: 8.96 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 26.55
FLML's P/B is ranked lower than
99.99% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 2.56 vs. FLML: 26.55 )
Ranked among companies with meaningful P/B only.
FLML' s P/B Range Over the Past 10 Years
Min: 1.83  Med: 4.78 Max: 71.24
Current: 26.55
1.83
71.24
P/S 4.04
FLML's P/S is ranked higher than
74% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. FLML: 4.04 )
Ranked among companies with meaningful P/S only.
FLML' s P/S Range Over the Past 10 Years
Min: 2.3  Med: 7.13 Max: 759.5
Current: 4.04
2.3
759.5
PFCF 11.16
FLML's PFCF is ranked higher than
79% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 28.77 vs. FLML: 11.16 )
Ranked among companies with meaningful PFCF only.
FLML' s PFCF Range Over the Past 10 Years
Min: 11.54  Med: 25.85 Max: 210.67
Current: 11.16
11.54
210.67
POCF 10.48
FLML's POCF is ranked higher than
79% of the 380 Companies
in the Global Biotechnology industry.

( Industry Median: 27.35 vs. FLML: 10.48 )
Ranked among companies with meaningful POCF only.
FLML' s POCF Range Over the Past 10 Years
Min: 10.87  Med: 22.71 Max: 50.65
Current: 10.48
10.87
50.65
Current Ratio 2.51
FLML's Current Ratio is ranked lower than
68% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. FLML: 2.51 )
Ranked among companies with meaningful Current Ratio only.
FLML' s Current Ratio Range Over the Past 10 Years
Min: 0.57  Med: 2.68 Max: 6.76
Current: 2.51
0.57
6.76
Quick Ratio 2.40
FLML's Quick Ratio is ranked lower than
65% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. FLML: 2.40 )
Ranked among companies with meaningful Quick Ratio only.
FLML' s Quick Ratio Range Over the Past 10 Years
Min: 0.52  Med: 2.61 Max: 6.7
Current: 2.4
0.52
6.7
Days Inventory 354.48
FLML's Days Inventory is ranked lower than
90% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. FLML: 354.48 )
Ranked among companies with meaningful Days Inventory only.
FLML' s Days Inventory Range Over the Past 10 Years
Min: 51.05  Med: 100.82 Max: 1457.72
Current: 354.48
51.05
1457.72
Days Sales Outstanding 15.95
FLML's Days Sales Outstanding is ranked higher than
86% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. FLML: 15.95 )
Ranked among companies with meaningful Days Sales Outstanding only.
FLML' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.95  Med: 74.39 Max: 541.87
Current: 15.95
39.95
541.87
Days Payable 673.37
FLML's Days Payable is ranked higher than
97% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. FLML: 673.37 )
Ranked among companies with meaningful Days Payable only.
FLML' s Days Payable Range Over the Past 10 Years
Min: 180.56  Med: 413.72 Max: 3311.63
Current: 673.37
180.56
3311.63

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.79
FLML's Price/Median PS Value is ranked higher than
56% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 0.87 vs. FLML: 0.79 )
Ranked among companies with meaningful Price/Median PS Value only.
FLML' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.24  Med: 0.98 Max: 13.18
Current: 0.79
0.24
13.18
Price/Graham Number 2.18
FLML's Price/Graham Number is ranked higher than
52% of the 407 Companies
in the Global Biotechnology industry.

( Industry Median: 2.23 vs. FLML: 2.18 )
Ranked among companies with meaningful Price/Graham Number only.
FLML' s Price/Graham Number Range Over the Past 10 Years
Min: 0.63  Med: 2.41 Max: 15
Current: 2.18
0.63
15
Earnings Yield (Greenblatt) (%) -4.47
FLML's Earnings Yield (Greenblatt) (%) is ranked higher than
56% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. FLML: -4.47 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
FLML' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -4.98  Med: 3.30 Max: 3.9
Current: -4.47
-4.98
3.9

More Statistics

Revenue(Mil) $94
EPS $ -1.11
Beta0.72
Short Percentage of Float2.38%
52-Week Range $8.71 - 26.09
Shares Outstanding(Mil)40.19

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 173 109 174 180
EPS($) 0.97 0.35 1.05 1.10
EPS without NRI($) 0.97 0.35 1.05 1.10

Business Description

Industry: Biotechnology » Biotechnology
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:FL3.Germany,
Flamel Technologies SA was incorporated as a Societe Anonyme or SA, a form of corporation under the laws of the Republic of France in August 1990 as Flamel Technologies S.A. The Company is a specialty pharmaceutical company with a history in drug delivery, working on the development of safer and more efficacious formulations. The acquisition of Éclat on March 13, 2012 has created a more vertically integrated company, benefiting from greater development and commercial expertise and more near-term and mid-term potential value creating catalysts. Since its acquisition of Eclat, Flamel is now engaged in not only on the development and licensing of versatile, proprietary drug delivery platforms but also on the development of novel, high-value products based on those delivery platforms. Bloxiverz, the Company first NDA approval from the portfolio of Eclat products acquired in March 2012. Bloxiverz's NDA was filed in August 2012 and approved by the FDA on May 2013. The launch of Bloxiverz commenced in July 2013. Bloxiverz is a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Bloxiverz is the first and only FDA-approved version of neostigmine methylsulfate, even though other versions of neostigmine have been on the market as unapproved, grandfathered products under the Food, Drug and Cosmetic Act of 1938. Coreg CR, the lead product using its Micropump drug delivery platform. Coreg CR is an extended-release formulation once-a-day of Coreg a non-selective antagonist of Beta 1, Beta 2 adrenergic receptors and a selective antagonist of Alpha 1 adrenergic receptors. The Company faces competition from Actavis, Alkermes, BioAlliance Pharma, Depomed, Ethypharm, Octoplus, Veloxis Pharmaceuticals, Nektar Therapeutics. The Company owns and develops drug delivery platforms that are able to tackle key challenges in the formulation, in various dosage forms of a broad range of drugs novel, already-marketed, or off-patent that includes Micropump. During the 2013 the Company has 395 patents in total. The design, testing, manufacturing and marketing of certain new or substantially modified drugs, biological products or medical devices must be approved, cleared or certified by regulatory agencies, regulatory authorities and Notified Bodies under applicable laws and regulations, the requirements of which may vary from country to country.
» More Articles for FLML

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Flamel Technologies to Present at RBC Capital Markets' 2016 Global Healthcare Conference Feb 11 2016
Pharmaceutical company with Chesterfield presence makes $20 million acquisition Feb 09 2016
FLAMEL TECHNOLOGIES SA Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 09 2016
Flamel Technologies Acquires FSC Pediatrics Feb 08 2016
Edited Transcript of FLML earnings conference call or presentation 19-Mar-15 2:00pm GMT Feb 01 2016
Flamel Technologies (FLML) in Focus: Stock Gains 5.8% Jan 15 2016
5 Stocks to Trade for Breakout Gains Jan 15 2016
FLAMEL TECHNOLOGIES SA Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 11 2016
Flamel Technologies Provides Update on Corporate Progress Jan 08 2016
[$$] Flamel Stock Fall Looks Overdone Jan 04 2016
Flamel Technologies (FLML) in Focus: Stock Tanks 15.7% Jan 04 2016
Roth Capital Defends Flamel Tech Selloff, Says It's 'Overdone' And Worth $21 Per Share Dec 31 2015
A Look At Four Stocks Down In Last Trading Session of 2015 Dec 31 2015
Flamel Technologies Announces Positive Interim Results of a First-in-Man Clinical Trial with... Dec 22 2015
Flamel Technologies Announces Positive Interim Results of a First-in-Man Clinical Trial With... Dec 22 2015
Flamel Technologies SA Earnings Analysis: Q3, 2015 By the Numbers Dec 21 2015
A Look at Top Picks of This Billion-Dollar Healthcare-Focused Fund Dec 11 2015
FLAMEL TECHNOLOGIES SA Financials Dec 08 2015
Hedge Funds Are Dumping Flamel Technologies S.A. (ADR) (FLML) Nov 28 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK